$95.00
Purity ≥ 99 percent by HPLC with mass spectrometry validation
Sourced and assembled in the United States with internal quality verification
Appearance: white to off-white
Storage: –20 °C, dry, protected from light
COA and full traceability included
These areas represent research involving authenticated tirzepatide and must not be presented as medical claims for this product.
Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. 2018. PMID: 30473097.
Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. 2020. PMID: 32730231.
Rosenstock J, et al. Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide. 2021. PMID: 34186022.
These products are for laboratory research only and not intended for medical use. They must be handled by qualified professionals in controlled laboratory environments. This compound has not been evaluated by the FDA and is not approved for human or veterinary use.
This product is supplied strictly for laboratory research. It is not intended for human or veterinary use, medical treatment, compounding, self-administration or diagnostic purposes.
Tirzepatide is used as the active ingredient in FDA-approved prescription medicines. However, this Vitera Labs research vial is not FDA-approved and must not be represented as a generic or equivalent version of an approved product.
The photographed vial is labeled as containing 10 mg of tirzepatide.
The identity, peptide content and purity should be verified by a lot-specific CoA containing HPLC and mass-spectrometry results. Sterility, endotoxin or microbial claims require separate validated testing.
Storage must follow the lot-specific stability documentation. The material should be protected from conditions known to degrade peptides, including uncontrolled temperature, moisture, light exposure and unnecessary freeze-thaw cycling.
No fixed post-preparation stability period should be published without supporting data.
Only trained laboratory personnel should prepare the material. Solvent, buffer, concentration, pH and handling conditions should be selected according to the experimental protocol and the product’s analytical documentation.
This information is not intended to provide instructions for administration.
Published tirzepatide research has included:
The clinical literature concerns regulated investigational or approved pharmaceutical preparations, not this vial.
No. This is a research-use material and is not an FDA-approved medication, generic drug or compounded prescription product.
Tirzepatide is a synthetic peptide investigated as a dual agonist of the GIP and GLP-1 receptors.
Research indicates that its signaling profile is not simply identical at both receptors; studies have examined differences in receptor potency, signaling bias and receptor internalization.
$60.00
